NASDAQGMAB

Genmab (GMAB) and partner AbbVie (NYSE:ABBV) have received U.S. FDA approval for their monoclonal antibody Epkinly (epcoritamab-bysp) for the treatment of adults with relapsed or refractory follicular lymphoma. The approval is based on results from Phase 1/2 EPCORE NHL-1 study, which demonstrated durable, clinically meaningful treatment responses in patients withContinue Reading